Efficacy and safety of ODM-101 compared to a standard combination (Stalevo); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson's disease and end-of-dose motor fluctuations.

Trial Profile

Efficacy and safety of ODM-101 compared to a standard combination (Stalevo); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson's disease and end-of-dose motor fluctuations.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Levodopa/carbidopa/entacapone (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms PARPOC
  • Most Recent Events

    • 23 Mar 2013 Primary endpoint 'Off-time' has been met.
    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 13 Jan 2013 Planned number of patients changed from 100 to 117 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top